All In Biotech

Free tool

FAERS Monitor: Acular

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019700 or its brand name (Acular, Ketorolac Tromethamine). Reports on generic versions are filed under their own applications.

Reports

5,005

Serious

2,966

59% of reports

Hospitalization

1,430

Death reported

295

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective535
  • drug hypersensitivity325
  • nausea276
  • headache267
  • pain265
  • fatigue251
  • dyspnoea240
  • treatment failure211
  • off label use186
  • eye pain183
  • vomiting177
  • diarrhoea164
  • product dose omission issue151
  • dizziness147
  • eye irritation144

Reports by year received

View as table
YearReports
200459
200596
200690
200780
2008105
2009129
2010119
2011178
2012210
201381
2014111
2015117
2016378
2017244
2018226
2019320
2020512
2021245
2022323
2023381
2024363
2025376
2026262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,154 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eye painSignal18313.711.92,135
treatment failureSignal21110.79.41,854
eye irritationSignal14410.59.01,234
drug hypersensitivitySignal3257.16.41,700
product dose omission issueSignal1512.21.894
pain2651.81.699
headache2671.81.695
dyspnoea2401.81.684
drug ineffective5351.71.6166
vomiting1771.61.438
nausea2761.51.342
fatigue2511.41.224
dizziness1471.21.17
diarrhoea1641.10.91
off label use1860.90.82

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.